This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

People with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood have a lower risk of dementia, including ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...